You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永泰生物-B(06978.HK)擬成立合營企業用於進駐腫瘤治療伴隨診斷市場

格隆匯6月2日丨永泰生物-B(06978.HK)公吿,於2022年6月2日,公司的間接全資附屬公司北京永泰生物製品有限公司與上海新開源精準醫療有限公司訂立合營協議。上海新開源為博愛新開源醫療科技集團股份有限公司的全資附屬公司。新開源醫療為一家於深圳證券交易所上市的公司(股份代號:300109),併為公司首次公開發售前投資者之一新開源醫療香港有限公司的母公司。

根據合營協議的條款,北京永泰與上海新開源同意於上海成立合營企業,用於進駐腫瘤治療伴隨診斷市場,以提供腫瘤治療伴隨診斷產品和服務為目標。合營企業的註冊資本為人民幣1000萬元,其中上海新開源應以現金注資方式出資人民幣700萬元及北京永泰應以技術注資方式出資人民幣300萬元,並分別按其於合營企業70%及30%的建議股權比例作出。

合營企業將主要從事腫瘤治療伴隨診斷。公司認為,通過訂立合營協議及成立合營企業,公司將受益於進駐腫瘤治療伴隨診斷市場,以提供腫瘤治療伴隨診斷產品和服務為目標。此次合作有利於擴大及完善公司市場佈局,將對公司的持續經營產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account